Matches in DBpedia 2016-04 for { <http://dbpedia.org/resource/Levodopa-induced_dyskinesia> ?p ?o }
Showing triples 1 to 48 of
48
with 100 triples per page.
- Levodopa-induced_dyskinesia abstract "Levodopa-induced dyskinesia is a form of dyskinesia associated with levodopa used to treat Parkinson's disease. It often involves hyperkinetic movements, including chorea, dystonia, and athetosis.In the context of Parkinson's disease (PD), dyskinesia is often the result of chronic L-DOPA (levodopa) therapy. These motor fluctuations occur in more than half of PD patients after 5–10 years of L-DOPA treatment, with the percentage of affected patients increasing over time. Based on the relationship with levodopa dosing, dyskinesia most commonly occurs at the time of peak L-DOPA plasma concentrations and is thus referred to as peak-dose dyskinesia (PDD). As patients advance, they may evidence diphasic dyskinesia (DD), which occur when the drug concentration rises or falls. If dyskinesia becomes too severe or impairs the patient's quality of life, a reduction in L-Dopa might be necessary, however this may be accompanied by a worsening of motor performance. Therefore, once established, LID is difficult to treat. Amongst pharmacological treatment, N-methyl-D-aspartate (NMDA) antagonist, (a glutamate receptor), amantadine, has been proven to be clinically effective in a small number of placebo controlled randomized controlled trials, while many others have only shown promise in animal models. Attempts to moderate dyskinesia by the use of other treatments such as bromocriptine (Parlodel), a dopamine agonist, appears to be ineffective. In order to avoid dyskinesia, patients with the young-onset form of the disease or young-onset Parkinson's disease (YOPD) are often hesitant to commence L-DOPA therapy until absolutely necessary for fear of suffering severe dyskinesia later on. Alternatives include the use of DA agonists (i.e. ropinirole or pramipexole) in lieu of early L-DOPA use which delays the use of L-DOPA. Additionally, a review (Stocchi, F., Clin Neuropharmacol, 2010, 33, 198) shows that highly soluble L-DOPA prodrugs may be effective in avoiding the in vivo blood concentration swings that potentially lead to motor fluctuations and dyskinesia.".
- Levodopa-induced_dyskinesia wikiPageID "25332361".
- Levodopa-induced_dyskinesia wikiPageLength "11147".
- Levodopa-induced_dyskinesia wikiPageOutDegree "36".
- Levodopa-induced_dyskinesia wikiPageRevisionID "696344589".
- Levodopa-induced_dyskinesia wikiPageWikiLink Amantadine.
- Levodopa-induced_dyskinesia wikiPageWikiLink Anticonvulsant.
- Levodopa-induced_dyskinesia wikiPageWikiLink Antiparkinson.
- Levodopa-induced_dyskinesia wikiPageWikiLink Athetosis.
- Levodopa-induced_dyskinesia wikiPageWikiLink Blood_plasma.
- Levodopa-induced_dyskinesia wikiPageWikiLink Bromocriptine.
- Levodopa-induced_dyskinesia wikiPageWikiLink Category:Parkinsons_disease.
- Levodopa-induced_dyskinesia wikiPageWikiLink Chorea.
- Levodopa-induced_dyskinesia wikiPageWikiLink Concentration.
- Levodopa-induced_dyskinesia wikiPageWikiLink Deep_brain_stimulation.
- Levodopa-induced_dyskinesia wikiPageWikiLink Dopamine_agonist.
- Levodopa-induced_dyskinesia wikiPageWikiLink Dyskinesia.
- Levodopa-induced_dyskinesia wikiPageWikiLink Dystonia.
- Levodopa-induced_dyskinesia wikiPageWikiLink FOSB.
- Levodopa-induced_dyskinesia wikiPageWikiLink Globus_pallidus.
- Levodopa-induced_dyskinesia wikiPageWikiLink Glutamate_receptor.
- Levodopa-induced_dyskinesia wikiPageWikiLink L-DOPA.
- Levodopa-induced_dyskinesia wikiPageWikiLink Levetiracetam.
- Levodopa-induced_dyskinesia wikiPageWikiLink Mavoglurant.
- Levodopa-induced_dyskinesia wikiPageWikiLink N-Methyl-D-aspartic_acid.
- Levodopa-induced_dyskinesia wikiPageWikiLink Nigrostriatal_pathway.
- Levodopa-induced_dyskinesia wikiPageWikiLink Novartis.
- Levodopa-induced_dyskinesia wikiPageWikiLink Oscillation.
- Levodopa-induced_dyskinesia wikiPageWikiLink Parkinsons_disease.
- Levodopa-induced_dyskinesia wikiPageWikiLink Peak-dose_dyskinesia.
- Levodopa-induced_dyskinesia wikiPageWikiLink Signal_transduction.
- Levodopa-induced_dyskinesia wikiPageWikiLink Striatum.
- Levodopa-induced_dyskinesia wikiPageWikiLink Subthalamic_nucleus.
- Levodopa-induced_dyskinesia wikiPageWikiLink Viral_vector.
- Levodopa-induced_dyskinesia wikiPageWikiLinkText "Levodopa-induced dyskinesia".
- Levodopa-induced_dyskinesia wikiPageWikiLinkText "levodopa-induced dyskinesia".
- Levodopa-induced_dyskinesia wikiPageWikiLinkText "peak-dose dyskinesias".
- Levodopa-induced_dyskinesia wikiPageUsesTemplate Template:Reflist.
- Levodopa-induced_dyskinesia wikiPageUsesTemplate Template:Use_dmy_dates.
- Levodopa-induced_dyskinesia subject Category:Parkinsons_disease.
- Levodopa-induced_dyskinesia hypernym Form.
- Levodopa-induced_dyskinesia comment "Levodopa-induced dyskinesia is a form of dyskinesia associated with levodopa used to treat Parkinson's disease. It often involves hyperkinetic movements, including chorea, dystonia, and athetosis.In the context of Parkinson's disease (PD), dyskinesia is often the result of chronic L-DOPA (levodopa) therapy. These motor fluctuations occur in more than half of PD patients after 5–10 years of L-DOPA treatment, with the percentage of affected patients increasing over time.".
- Levodopa-induced_dyskinesia label "Levodopa-induced dyskinesia".
- Levodopa-induced_dyskinesia sameAs Q6535765.
- Levodopa-induced_dyskinesia sameAs m.09gnvv_.
- Levodopa-induced_dyskinesia sameAs Q6535765.
- Levodopa-induced_dyskinesia wasDerivedFrom Levodopa-induced_dyskinesia?oldid=696344589.
- Levodopa-induced_dyskinesia isPrimaryTopicOf Levodopa-induced_dyskinesia.